This session is supported by an independent educational grant from Incyte.
Patients with polycythemia vera (PV) have shorten survival and experience a variety of disease-related symptoms that reduce the quality of life. This program will review the symptoms and the validated tools available to assess symptom burden in patients with PV. While cytoreductive therapy with hydroxyurea is recommended as first-line, 25% of patients develop resistance or intolerance, which is associated with poor outcomes. In this program expert faculty will discuss the European LeukemiaNet (ELN) criteria for hydroxyurea resistance or intolerance and current guideline recommendations for the treatment of PV. The faculty also will review the safety and efficacy of second-line therapies including Janus-associated kinase (JAK) inhibitors for the treatment of PV.
Nurse practitioners, physician assistants, pharmacists, and nurses working in all phases of oncology care.
After completing the activity, the participant should be better able to:
Apply validated tools to assess symptom burden in patients with polycythemia vera (PV)
Identify patients with PV progression and/or resistance or intolerance to standard cytoreductive therapy
Select optimal treatment strategies for PV patients who are either resistant or intolerant to hydroxyurea
Accreditor Disclosure of Conflicts of Interest Policy
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members’ relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
Dr. Lyle discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 12 months.
Content Chair Robyn Scherber, MD, MPH Assistant Professor of Medicine UT Health Mays Cancer Center/MD Anderson Houston, TX
Dr. Scherber has served as a Consultant for Incyte and on an Advisory Board for Novartis.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content disclose no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 12 months.
AMA PRA Category 1 Credit(s)TM
Horizon CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Horizon CME designates this activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 65% or greater) and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, please contact Cara Williams, PharmD at Horizon CME (503) 659-5558.